Functional genomic screening identifies dual leucine zipper kinase as a key mediator of retinal ganglion cell death

Derek S. Welsbie, Zhiyong Yang, Yan Ge, Katherine L. Mitchell, Xinrong Zhou, Scott E. Martin, Cynthia Ann Berlinicke, Laszlo Hackler, John Fuller, Jie Fu, Li Hui Cao, Bing Han, Douglas Auld, Tian Xue, Syu Ichi Hirai, Lucie Germain, Caroline Simard-Bisson, Richard Blouin, Judy V. Nguyen, Chung Ha O Davis & 12 others Raymond A. Enke, Sanford L. Boye, Shannath L Merbs, Nicholas Marsh-Armstrong, William W. Hauswirth, Aaron Diantonio, Robert W. Nickells, James Inglese, Justin S Hanes, King-Wai Yau, Harry A Quigley, Donald J Zack

Research output: Contribution to journalArticle

Abstract

Glaucoma, a major cause of blindness worldwide, is a neurodegenerative optic neuropathy in which vision loss is caused by loss of retinal ganglion cells (RGCs). To better define the pathways mediating RGC death and identify targets for the development of neuroprotective drugs, we developed a high-throughput RNA interference screen with primary RGCs and used it to screen the full mouse kinome. The screen identified dual leucine zipper kinase (DLK) as a key neuroprotective target in RGCs. In cultured RGCs, DLK signaling is both necessary and sufficient for cell death. DLK undergoes robust posttranscriptional up-regulation in response to axonal injury in vitro and in vivo. Using a conditional knockout approach, we confirmed that DLK is required for RGC JNK activation and cell death in a rodent model of optic neuropathy. In addition, tozasertib, a small molecule protein kinase inhibitor with activity against DLK, protects RGCs from cell death in rodent glaucoma and traumatic optic neuropathy models. Together, our results establish a previously undescribed drug/drug target combination in glaucoma, identify an early marker of RGC injury, and provide a starting point for the development of more specific neuroprotective DLK inhibitors for the treatment of glaucoma, nonglaucomatous forms of optic neuropathy, and perhaps other CNS neurodegenerations.

Original languageEnglish (US)
Pages (from-to)4045-4050
Number of pages6
JournalProceedings of the National Academy of Sciences of the United States of America
Volume110
Issue number10
DOIs
StatePublished - Mar 5 2013

Fingerprint

Leucine Zippers
Retinal Ganglion Cells
Cell Death
Phosphotransferases
Glaucoma
Optic Nerve Diseases
Rodentia
Optic Nerve Injuries
Wounds and Injuries
Neuroprotective Agents
Drug Combinations
Blindness
Protein Kinase Inhibitors
RNA Interference
Cultured Cells
Up-Regulation

Keywords

  • Drug discovery
  • MAP3K12
  • Neuroprotection

ASJC Scopus subject areas

  • General

Cite this

Functional genomic screening identifies dual leucine zipper kinase as a key mediator of retinal ganglion cell death. / Welsbie, Derek S.; Yang, Zhiyong; Ge, Yan; Mitchell, Katherine L.; Zhou, Xinrong; Martin, Scott E.; Berlinicke, Cynthia Ann; Hackler, Laszlo; Fuller, John; Fu, Jie; Cao, Li Hui; Han, Bing; Auld, Douglas; Xue, Tian; Hirai, Syu Ichi; Germain, Lucie; Simard-Bisson, Caroline; Blouin, Richard; Nguyen, Judy V.; Davis, Chung Ha O; Enke, Raymond A.; Boye, Sanford L.; Merbs, Shannath L; Marsh-Armstrong, Nicholas; Hauswirth, William W.; Diantonio, Aaron; Nickells, Robert W.; Inglese, James; Hanes, Justin S; Yau, King-Wai; Quigley, Harry A; Zack, Donald J.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 110, No. 10, 05.03.2013, p. 4045-4050.

Research output: Contribution to journalArticle

Welsbie, DS, Yang, Z, Ge, Y, Mitchell, KL, Zhou, X, Martin, SE, Berlinicke, CA, Hackler, L, Fuller, J, Fu, J, Cao, LH, Han, B, Auld, D, Xue, T, Hirai, SI, Germain, L, Simard-Bisson, C, Blouin, R, Nguyen, JV, Davis, CHO, Enke, RA, Boye, SL, Merbs, SL, Marsh-Armstrong, N, Hauswirth, WW, Diantonio, A, Nickells, RW, Inglese, J, Hanes, JS, Yau, K-W, Quigley, HA & Zack, DJ 2013, 'Functional genomic screening identifies dual leucine zipper kinase as a key mediator of retinal ganglion cell death', Proceedings of the National Academy of Sciences of the United States of America, vol. 110, no. 10, pp. 4045-4050. https://doi.org/10.1073/pnas.1211284110
Welsbie, Derek S. ; Yang, Zhiyong ; Ge, Yan ; Mitchell, Katherine L. ; Zhou, Xinrong ; Martin, Scott E. ; Berlinicke, Cynthia Ann ; Hackler, Laszlo ; Fuller, John ; Fu, Jie ; Cao, Li Hui ; Han, Bing ; Auld, Douglas ; Xue, Tian ; Hirai, Syu Ichi ; Germain, Lucie ; Simard-Bisson, Caroline ; Blouin, Richard ; Nguyen, Judy V. ; Davis, Chung Ha O ; Enke, Raymond A. ; Boye, Sanford L. ; Merbs, Shannath L ; Marsh-Armstrong, Nicholas ; Hauswirth, William W. ; Diantonio, Aaron ; Nickells, Robert W. ; Inglese, James ; Hanes, Justin S ; Yau, King-Wai ; Quigley, Harry A ; Zack, Donald J. / Functional genomic screening identifies dual leucine zipper kinase as a key mediator of retinal ganglion cell death. In: Proceedings of the National Academy of Sciences of the United States of America. 2013 ; Vol. 110, No. 10. pp. 4045-4050.
@article{b6eff85bd18f40c78c07f1aa6ceddf25,
title = "Functional genomic screening identifies dual leucine zipper kinase as a key mediator of retinal ganglion cell death",
abstract = "Glaucoma, a major cause of blindness worldwide, is a neurodegenerative optic neuropathy in which vision loss is caused by loss of retinal ganglion cells (RGCs). To better define the pathways mediating RGC death and identify targets for the development of neuroprotective drugs, we developed a high-throughput RNA interference screen with primary RGCs and used it to screen the full mouse kinome. The screen identified dual leucine zipper kinase (DLK) as a key neuroprotective target in RGCs. In cultured RGCs, DLK signaling is both necessary and sufficient for cell death. DLK undergoes robust posttranscriptional up-regulation in response to axonal injury in vitro and in vivo. Using a conditional knockout approach, we confirmed that DLK is required for RGC JNK activation and cell death in a rodent model of optic neuropathy. In addition, tozasertib, a small molecule protein kinase inhibitor with activity against DLK, protects RGCs from cell death in rodent glaucoma and traumatic optic neuropathy models. Together, our results establish a previously undescribed drug/drug target combination in glaucoma, identify an early marker of RGC injury, and provide a starting point for the development of more specific neuroprotective DLK inhibitors for the treatment of glaucoma, nonglaucomatous forms of optic neuropathy, and perhaps other CNS neurodegenerations.",
keywords = "Drug discovery, MAP3K12, Neuroprotection",
author = "Welsbie, {Derek S.} and Zhiyong Yang and Yan Ge and Mitchell, {Katherine L.} and Xinrong Zhou and Martin, {Scott E.} and Berlinicke, {Cynthia Ann} and Laszlo Hackler and John Fuller and Jie Fu and Cao, {Li Hui} and Bing Han and Douglas Auld and Tian Xue and Hirai, {Syu Ichi} and Lucie Germain and Caroline Simard-Bisson and Richard Blouin and Nguyen, {Judy V.} and Davis, {Chung Ha O} and Enke, {Raymond A.} and Boye, {Sanford L.} and Merbs, {Shannath L} and Nicholas Marsh-Armstrong and Hauswirth, {William W.} and Aaron Diantonio and Nickells, {Robert W.} and James Inglese and Hanes, {Justin S} and King-Wai Yau and Quigley, {Harry A} and Zack, {Donald J}",
year = "2013",
month = "3",
day = "5",
doi = "10.1073/pnas.1211284110",
language = "English (US)",
volume = "110",
pages = "4045--4050",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
number = "10",

}

TY - JOUR

T1 - Functional genomic screening identifies dual leucine zipper kinase as a key mediator of retinal ganglion cell death

AU - Welsbie, Derek S.

AU - Yang, Zhiyong

AU - Ge, Yan

AU - Mitchell, Katherine L.

AU - Zhou, Xinrong

AU - Martin, Scott E.

AU - Berlinicke, Cynthia Ann

AU - Hackler, Laszlo

AU - Fuller, John

AU - Fu, Jie

AU - Cao, Li Hui

AU - Han, Bing

AU - Auld, Douglas

AU - Xue, Tian

AU - Hirai, Syu Ichi

AU - Germain, Lucie

AU - Simard-Bisson, Caroline

AU - Blouin, Richard

AU - Nguyen, Judy V.

AU - Davis, Chung Ha O

AU - Enke, Raymond A.

AU - Boye, Sanford L.

AU - Merbs, Shannath L

AU - Marsh-Armstrong, Nicholas

AU - Hauswirth, William W.

AU - Diantonio, Aaron

AU - Nickells, Robert W.

AU - Inglese, James

AU - Hanes, Justin S

AU - Yau, King-Wai

AU - Quigley, Harry A

AU - Zack, Donald J

PY - 2013/3/5

Y1 - 2013/3/5

N2 - Glaucoma, a major cause of blindness worldwide, is a neurodegenerative optic neuropathy in which vision loss is caused by loss of retinal ganglion cells (RGCs). To better define the pathways mediating RGC death and identify targets for the development of neuroprotective drugs, we developed a high-throughput RNA interference screen with primary RGCs and used it to screen the full mouse kinome. The screen identified dual leucine zipper kinase (DLK) as a key neuroprotective target in RGCs. In cultured RGCs, DLK signaling is both necessary and sufficient for cell death. DLK undergoes robust posttranscriptional up-regulation in response to axonal injury in vitro and in vivo. Using a conditional knockout approach, we confirmed that DLK is required for RGC JNK activation and cell death in a rodent model of optic neuropathy. In addition, tozasertib, a small molecule protein kinase inhibitor with activity against DLK, protects RGCs from cell death in rodent glaucoma and traumatic optic neuropathy models. Together, our results establish a previously undescribed drug/drug target combination in glaucoma, identify an early marker of RGC injury, and provide a starting point for the development of more specific neuroprotective DLK inhibitors for the treatment of glaucoma, nonglaucomatous forms of optic neuropathy, and perhaps other CNS neurodegenerations.

AB - Glaucoma, a major cause of blindness worldwide, is a neurodegenerative optic neuropathy in which vision loss is caused by loss of retinal ganglion cells (RGCs). To better define the pathways mediating RGC death and identify targets for the development of neuroprotective drugs, we developed a high-throughput RNA interference screen with primary RGCs and used it to screen the full mouse kinome. The screen identified dual leucine zipper kinase (DLK) as a key neuroprotective target in RGCs. In cultured RGCs, DLK signaling is both necessary and sufficient for cell death. DLK undergoes robust posttranscriptional up-regulation in response to axonal injury in vitro and in vivo. Using a conditional knockout approach, we confirmed that DLK is required for RGC JNK activation and cell death in a rodent model of optic neuropathy. In addition, tozasertib, a small molecule protein kinase inhibitor with activity against DLK, protects RGCs from cell death in rodent glaucoma and traumatic optic neuropathy models. Together, our results establish a previously undescribed drug/drug target combination in glaucoma, identify an early marker of RGC injury, and provide a starting point for the development of more specific neuroprotective DLK inhibitors for the treatment of glaucoma, nonglaucomatous forms of optic neuropathy, and perhaps other CNS neurodegenerations.

KW - Drug discovery

KW - MAP3K12

KW - Neuroprotection

UR - http://www.scopus.com/inward/record.url?scp=84874629422&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84874629422&partnerID=8YFLogxK

U2 - 10.1073/pnas.1211284110

DO - 10.1073/pnas.1211284110

M3 - Article

VL - 110

SP - 4045

EP - 4050

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 10

ER -